Relmada Therapeutics (RLMD) News Today $2.85 -0.13 (-4.36%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Relmada Therapeutics to Present at Jefferies London Healthcare ConferenceNovember 20 at 12:27 AM | markets.businessinsider.comRelmada Therapeutics initiates Phase 1 dosing with REL-P11November 14, 2024 | markets.businessinsider.comRelmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic DiseaseNovember 14, 2024 | globenewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | msn.comRelmada Therapeutics: Strong Buy on Promising Pipeline and Financial StabilityNovember 11, 2024 | markets.businessinsider.comRelmada Therapeutics, Inc. (RLMD) Q3 2024 Earnings Call TranscriptNovember 10, 2024 | seekingalpha.comRelmada Therapeutics Inc. Reports Q3 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | prnewswire.comRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comA Look Ahead: Relmada Therapeutics's Earnings ForecastNovember 6, 2024 | benzinga.comRelmada Therapeutics (RLMD) to Release Quarterly Earnings on ThursdayRelmada Therapeutics (NASDAQ:RLMD) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 5, 2024 | marketbeat.comRelmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024November 4, 2024 | globenewswire.comQ3 Earnings Estimate for RLMD Issued By Leerink PartnrsRelmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Analysts at Leerink Partnrs dropped their Q3 2024 earnings estimates for Relmada Therapeutics in a research report issued on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per sOctober 18, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Stock Quotes, Forecast and News SummaryOctober 14, 2024 | benzinga.comHow To Find The Insider Trades That Consistently Outperform The Market – Under The RadarOctober 10, 2024 | benzinga.comRelmada Therapeutics (NASDAQ:RLMD) Shares Down 0.3% - What's Next?Relmada Therapeutics (NASDAQ:RLMD) Stock Price Down 0.3% - Here's WhyOctober 9, 2024 | marketbeat.comJefferies Upgrades Relmada Therapeutics (RLMD)September 18, 2024 | msn.comRelmada jumps as Jefferies upgrades on a potential turnaround storySeptember 18, 2024 | msn.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmSeptember 16, 2024 | prnewswire.comRelmada therapeutics CEO acquires shares worth over $395kSeptember 13, 2024 | uk.investing.comRelmada Therapeutics director buys $33,280 in company stockSeptember 13, 2024 | uk.investing.comInsider Spends US$395k Buying More Shares In Relmada TherapeuticsSeptember 13, 2024 | sg.finance.yahoo.comInsider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Acquires 8,194 Shares of StockSeptember 12, 2024 | insidertrades.comInsider Buying: CFO Maged Shenouda Acquires Shares of Relmada Therapeutics Inc (RLMD)September 12, 2024 | finance.yahoo.comRelmada Therapeutics Inc (RLMD) CEO Sergio Traversa Acquires 140,000 SharesSeptember 12, 2024 | finance.yahoo.comInsider Buying: Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Buys 8,194 Shares of StockRelmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) CFO Maged Shenouda purchased 8,194 shares of the stock in a transaction dated Monday, September 9th. The stock was acquired at an average cost of $2.55 per share, for a total transaction of $20,894.70. Following the transaction, the chief financial officer now owns 43,097 shares of the company's stock, valued at $109,897.35. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.September 11, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Trading 16.3% Higher Relmada Therapeutics (NASDAQ:RLMD) Shares Up 16.3%September 10, 2024 | marketbeat.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmSeptember 5, 2024 | globenewswire.comRLMD Sep 2024 5.000 put (RLMD240920P00005000)August 19, 2024 | finance.yahoo.comLeerink Partnrs Equities Analysts Lift Earnings Estimates for Relmada Therapeutics, Inc. (NASDAQ:RLMD)Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) - Stock analysts at Leerink Partnrs increased their Q3 2024 EPS estimates for Relmada Therapeutics in a note issued to investors on Wednesday, August 7th. Leerink Partnrs analyst M. Goodman now forecasts that the company will post earnings peAugust 12, 2024 | marketbeat.comEarnings call: Relmada advances on REL-1017 and REL-P11 clinical trialsAugust 11, 2024 | investing.comRelmada Therapeutics (NASDAQ:RLMD) Issues Earnings Results, Beats Estimates By $0.24 EPSRelmada Therapeutics (NASDAQ:RLMD - Get Free Report) announced its quarterly earnings results on Wednesday. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.24. During the same period in the previous year, the company posted ($0.84) EPS.August 10, 2024 | marketbeat.comOptimistic Outlook for Relmada Therapeutics: Strategic Trial Enhancements and Solid Financial PositionAugust 9, 2024 | markets.businessinsider.comRelmada Therapeutics, Inc. (RLMD) Q2 2024 Earnings Call TranscriptAugust 9, 2024 | seekingalpha.comRLMD Stock Earnings: Relmada Therapeutics Beats EPS for Q2 2024August 8, 2024 | markets.businessinsider.comRelmada Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateAugust 7, 2024 | finance.yahoo.comRelmada Therapeutics (RLMD) Scheduled to Post Quarterly Earnings on WednesdayRelmada Therapeutics (NASDAQ:RLMD) will be releasing earnings after the market closes on Wednesday, August 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=617623)August 6, 2024 | marketbeat.comRelmada Therapeutics to Report Second Quarter 2024 Financial Results on August 7, 2024August 5, 2024 | globenewswire.comShort Interest in Relmada Therapeutics, Inc. (NASDAQ:RLMD) Grows By 34.7%Relmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) was the recipient of a significant increase in short interest in July. As of July 15th, there was short interest totalling 1,360,000 shares, an increase of 34.7% from the June 30th total of 1,010,000 shares. Based on an average daily trading volume, of 103,600 shares, the short-interest ratio is presently 13.1 days.July 29, 2024 | marketbeat.comKuehn Law Encourages Investors of Relmada Therapeutics, Inc. to Contact Law FirmJuly 25, 2024 | prnewswire.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Short Interest Down 34.8% in JuneRelmada Therapeutics, Inc. (NASDAQ:RLMD - Get Free Report) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totalling 1,010,000 shares, a decline of 34.8% from the June 15th total of 1,550,000 shares. Based on an average daily volume of 104,700 shares, the days-to-cover ratio is currently 9.6 days.July 12, 2024 | marketbeat.comRelmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical PsychiatryJune 18, 2024 | prnewswire.comOpaleye Management Inc. Purchases 847,000 Shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD)Opaleye Management Inc. grew its position in Relmada Therapeutics, Inc. (NASDAQ:RLMD - Free Report) by 2,823.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 877,000 shares of the company's stock after acquiring an additioJune 15, 2024 | marketbeat.comRelmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 10, 2024 | prnewswire.comThe Goldman Sachs Group Downgrades Relmada Therapeutics (NASDAQ:RLMD) to SellThe Goldman Sachs Group downgraded shares of Relmada Therapeutics from a "neutral" rating to a "sell" rating and decreased their price target for the stock from $3.00 to $2.00 in a research note on Wednesday.June 5, 2024 | marketbeat.comRelmada Therapeutics (NASDAQ:RLMD) Trading Up 2.7%Relmada Therapeutics (NASDAQ:RLMD) Stock Price Up 2.7%June 4, 2024 | marketbeat.comRelmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare ConferenceJune 3, 2024 | prnewswire.com7 Penny Biotech Stocks to Triple Your InvestmentMay 28, 2024 | investorplace.comRelmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2024 Earnings Call TranscriptMay 27, 2024 | finance.yahoo.comBuy Rating Affirmed for Relmada Therapeutics on Strong Clinical Trials and Financial FootingMay 10, 2024 | markets.businessinsider.com Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Download Our Tesla Ebook For Free (Ad)Like many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost. To claim your copy free of charge simply follow this link. RLMD Media Mentions By Week RLMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RLMD News Sentiment▼0.000.46▲Average Medical News Sentiment RLMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RLMD Articles This Week▼31▲RLMD Articles Average Week Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Amylyx Pharmaceuticals News Ginkgo Bioworks News Alector News Q32 Bio News Contineum Therapeutics News Cryoport News Kamada News Alpha Teknova News biote News COMPASS Pathways News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RLMD) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
